TP53 and mutations in human cancer.

• Authors: Katarzyna Szymańska , Pierre Hainaut
• Languages of publication: EN

Abstracts

EN

TP53 is the most frequently mutated gene in human cancer, with a predominance of missense mutations scattered over 200 codons. In many cancers, specific mutation patterns can be identified, which are shaped by site-specific mutagenesis and by biological selection. In tobacco-related cancers (lung, head and neck), organ-specific patterns are observed, with many mutations compatible with the ones experimentally induced by tobacco carcinogens. In several other cancers, such as squamous cell carcinoma of the oesophagus or hepatocellular carcinoma (HCC), mutation patterns show geographic variations between regions of high and low incidence, suggesting a role for region-specific risk factors. HCC from high-incidence regions showing also a high prevalence of a specific Ser-249 TP53 mutation is one of the most striking examples of a mutagen fingerprint. All such assessments are useful to generate clues on the mutagenic mechanisms involved in human cancer. Moreover, it has been shown that DNA retrieved from plasma can be successfully used for detection of TP53 mutations, which gives hope for earlier more accurate detection of human cancers.

Keywords

EN

CF DNA; cancer; mutation fingerprint; mutation; Ser-249; TP53

• Publisher: Polish Biochemical Society
• Journal: Acta Biochimica Polonica
• Year: 2003
• Volume: 50
• Issue: 1
• Pages: 231-238

Dates

published

2003

received

2002-11-04

accepted

2003-02-09

Contributors

author

Katarzyna Szymańska

• Unit of Molecular Carcinogenesis, International Agency for Research on Cancer, Lyon, France

author

Pierre Hainaut

• Unit of Molecular Carcinogenesis, International Agency for Research on Cancer, Lyon, France

References

• Ambs S, Merriam WG, Bennett WP, Felley-Bosco E, Ogunfusika MO, Oser SM, Klein S, Shields PG, Billiar TR, Harris CC. (1998) Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. Cancer Res.; 58: 334-41.
• Anker P, Mulcahy H, Chen XQ, Stroun M. (1999) Detection of circulating tumour DNA in the blood (plasma/serum) of cancer patients. Cancer Metastasis Rev.; 18: 65-73.
• Appella E, Anderson CW. (2000) Signaling to p53: breaking the posttranslational modification code. Pathol Biol (Paris).; 48: 227-45.
• Cho Y, Gorina S, Jeffrey PD, Pavletich NP. (1994) Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science.; 265: 346-55.
• Daya-Grosjean L, Dumaz N, Sarasin A. (1995) The specificity of p53 mutation spectra in sunlight induced human cancers. J Photochem Photobiol B.; 28: 115-24.
• Denissenko MF, Koudriakova TB, Smith L, O'Connor TR, Riggs AD, Pfeifer GP. (1998) The p53 codon 249 mutational hotspot in hepatocellular carcinoma is not related to selective formation or persistence of aflatoxin B1 adducts. Oncogene.; 17: 3007-14.
• Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CAJ, Butel JS, Bradley A. (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature.; 356: 215-21.
• Giglia G, Dumaz N, Drougard C, Avril MF, Daya-Grosjean L, Sarasin A. (1998) p53 mutations in skin and internal tumors of xeroderma pigmentosum patients belonging to the complementation group C. Cancer Res.; 58: 4402-9.
• Greenblatt MS, Bennett WP, Hollstein M, Harris CC. (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res.; 54: 4855-78.
• Guimaraes DP, Hainaut P. (2002) TP53: a key gene in human cancer. Biochimie.; 84: 83-93.
• Hainaut P, Hollstein M. (2000) p53 and human cancer: the first ten thousand mutations. Adv Cancer Res.; 77: 81-137.
• Kirk GD, Camus-Randon AM, Mendy M, Goedert JJ, Merle P, Trepo C, Brechot C, Hainaut P, Montesano R. (2000) Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from The Gambia. J Natl Cancer Inst.; 92: 148-53.
• Levrero M, De Laurenzi V, Costanzo A, Gong J, Melino G, Wang JY. (1999) Structure, function and regulation of p63 and p73. Cell Death Differ.; 6: 1146-53.
• Montesano R, Hainaut P, Wild CP. (1997) Hepatocellular carcinoma: from gene to public health. J Natl Cancer Inst.; 89: 1844-51.
• Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. (2002) The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat.; 19: 607-14.
• Oren M, Rotter V. (1999) Introduction: p53 - the first twenty years. Cell Mol Life Sci.; 55: 9-11.
• Pfeifer GP, Denissenko MF, Olivier M, Tretyakova N, Hecht SS, Hainaut P. (2002) Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene.; 21: 7435-51.
• Pluquet O, Hainaut P. (2001) Genotoxic and non-genotoxic pathways of p53 induction. Cancer Lett.; 174: 1-15.
• Rideout WM 3rd, Coetzee GA, Olumi AF, Jones PA. (1990) 5-Methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science.; 249: 1288-90.
• Sherr CJ. (2000) The Pezcoller lecture: cancer cell cycles revisited. Cancer Res.; 60: 3689-95.
• Smith LE, Denissenko MF, Bennett WP, Li H, Amin S, Tang M, Pfeifer GP. (2000) Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. J Natl Cancer Inst.; 92: 803-11.